Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial [Yahoo! Finance]
Medincell to Host Videoconference on May 15, 2024, at 10:30 AM CEST to Discuss Company's Latest News, Outlook, and R&D Activities [Yahoo! Finance]
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $20.00 price target on the stock, up previously from $19.00.
Teva Pharmaceutical Industries Limited (NYSE: TEVA) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.